يعرض 1 - 10 نتائج من 18 نتيجة بحث عن '"slow delivery"', وقت الاستعلام: 0.74s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية

    المساهمون: Caso, Mf, Carotenuto, F, Di Nardo, P, Migliore, A, Aguilera, A, Lopez, Cm, Venanzi, M, Cavalieri, F, Rinaldi, A

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32486448; info:eu-repo/semantics/altIdentifier/wos/WOS:000554636600001; volume:10; issue:6; firstpage:1075; journal:NANOMATERIALS; info:eu-repo/grantAgreement/EC/H2020/690901; http://hdl.handle.net/2108/260536Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85086173980

  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5

    المساهمون: Oral Regenerative Medicine (ORM), Oral Cell Biology, Gu, Yifei, Wei, Lingfei, Zhang, Zheru, Van Dessel, Jeroen, DRIESEN, Ronald, LAMBRICHTS, Ivo, Jacobs, Reinhilde, Tian, Lei, SUN, Yi, Liu, Yuelian, POLITIS, Constantinus

    المصدر: Gu, Y, Wei, L, Zhang, Z, Van Dessel, J, Driesen, R B, Lambrichts, I, Jacobs, R, Tian, L, Sun, Y, Liu, Y & Politis, C 2022, ' BMP-2 incorporated biomimetic CaP coating functionalized 3D printed Ti6Al4V scaffold induces ectopic bone formation in a dog model ', Materials and Design, vol. 215, 110443, pp. 1-13 . https://doi.org/10.1016/j.matdes.2022.110443Test
    Materials and Design, 215:110443, 1-13. Elsevier BV
    Materials & Design, Vol 215, Iss, Pp 110443-(2022)

    وصف الملف: application/pdf

  6. 6
  7. 7
  8. 8

    المساهمون: Universidade Estadual Paulista (Unesp)

    المصدر: Repositório Institucional da UNESP
    Universidade Estadual Paulista (UNESP)
    instacron:UNESP
    Mujtaba, M, Khawar, K M, Camara, M C, Carvalho, L B, Fraceto, L F, Morsi, R E, Elsabee, M Z, Kaya, M, Labidi, J, Ullah, H & Wang, D 2020, ' Chitosan-based delivery systems for plants : A brief overview of recent advances and future directions ', International Journal of Biological Macromolecules, vol. 154, pp. 683-697 . https://doi.org/10.1016/j.ijbiomac.2020.03.128Test

  9. 9
    دورية أكاديمية
  10. 10
    دورية أكاديمية

    وصف الملف: application/pdf

    العلاقة: Li, Yan; Sun, Duxin; Palmisano, Maria; Zhou, Simon (2016). "Slow drug delivery decreased total body clearance and altered bioavailability of immediate‐ and controlled‐release oxycodone formulations." Pharmacology Research & Perspectives (1): n/a-n/a.; https://hdl.handle.net/2027.42/116943Test; Pharmacology Research & Perspectives; Poelaert J, Koopmans‐Klein G, Dioh A, Louis F, Gorissen M, Loge D, et al. ( 2015 ). Treatment with prolonged‐release oxycodone/naloxone improves pain relief and opioid‐induced constipation compared with prolonged‐release oxycodone in patients with chronic severe pain and laxative‐refractory constipation. Clin Ther 784 – 792.; Lofwall MR, Moody DE, Fang WB, Nuzzo PA, Walsh SL ( 2012 ). Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers. J Clin Pharmacol 52: 600 – 606.; Lux EA, Janecki M, Maritz MA ( 2014 ). Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double‐blind, multicenter, cross‐over, non‐inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release tablet. Curr Med Res Opin 30: 2365 – 2375.; Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR ( 1996 ). Characterization and validation of a pharmacokinetic model for controlled‐release oxycodone. Br J Clin Pharmacol 42: 747 – 756.; Mehta V, Alaward S, Kuravinakop S, Nikolic S ( 2014 ). Effect of a fixed‐dose opioid agonist/antagonist on constipation in patients on long‐term opioids for non‐malignant pain unable to tolerate laxatives. Pain Phys 17: 415 – 424.; Mundin GE, Smith KJ, Mysicka J, Heun G, Kramer M, Hahn U, et al. ( 2012 ). Validated in vitro/in vivo correlation of prolonged‐release oxycodone/naloxone with differing dissolution rates in relation to gastrointestinal transit times. Expert Opin Drug Metab Toxicol 8: 1495 – 1503.; Naito T, Tashiro M, Ishida T, Ohnishi K, Kawakami J ( 2013 ). Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone‐treated patients. J Clin Pharmacol 53: 812 – 818.; Pang KS, Rowland M. ( 1977 ) Hepatic clearance of drugs. I. Theoretical considerations of a “well‐stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 5: 625 – 653.; Radbruch L, Nauck F ( 2002 ). Morphine and alternative opioids in cancer pain: the EAPC recommendations. Schmerz 16: 186 – 193.; Ross FB, Smith MT ( 1997 ). The intrinsic antinociceptive effects of oxycodone appear to be kappa‐opioid receptor mediated. Pain 73: 151 – 157.; Smith MT ( 2008 ). Differences between and combinations of opioids re‐visited. Curr Opin Anaesthesiol. 21: 596 – 601.; Soderberg Lofdal KC, Andersson ML, Gustafsson LL ( 2013 ). Cytochrome P450‐mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications. Drugs 73: 533 – 543.; Stessel B, Theunissen M, Fiddelers AA, Joosten EA, Kessels AG, Gramke HF, et al. ( 2014 ). Controlled‐release oxycodone versus naproxen at home after ambulatory surgery: a randomized controlled trial. Curr Ther Res Clin Exp 76: 120 – 125.; Takala A, Kaasalainen V, Seppala T, Kalso E, Olkkola KT ( 1997 ). Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiol Scand 41: 309 – 312.; Tan Q, Jiang R, Xu M, Liu G, Li S, Nanosized Zhang J ( 2013 ). Sustained‐release pyridostigmine bromide microcapsules: process optimization and evaluation of characteristics. Int J Nanomed 8: 737 – 745.; Tegon G, Pulzato L, Passarella L, Guidolin D, Zusso M, Giusti P ( 2009 ). Randomized placebo‐controlled trial on local applications of opioids after hemorrhoidectomy. Tech Coloproctol 13: 219 – 224.; Trescot AM, Datta S, Lee M, Hansen H ( 2008 ). Opioid pharmacology. Pain Phys 11: S133 – S153.; Vallejo R, Barkin RL, Wang VC ( 2011 ). Pharmacology of opioids in the treatment of chronic pain syndromes. Pain Phys 14: E343 – E360.; Vk P ( 1987 ). The use of Weibull distribution to describe the in vivo absorption kinetics. J Pharmacokinet Biopharm 15: 681 – 686.; Zhou H ( 2003 ). Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol 43: 211 – 227.; Al‐Ghananeem AM, Malkawi AH, Crooks PA ( 2006 ). Effect of pH on sublingual absorption of oxycodone hydrochloride. AAPS Pharm Sci Tech 7: E23.; Bass A, Stark JG, Pixton GC, Sommerville KW, Zamora CA, Leibowitz M, et al. ( 2012 ). Dose proportionality and the effects of food on bioavailability of an immediate‐release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single‐dose, randomized, open‐label, 5‐way crossover study in healthy volunteers. Clin Ther 34: 1601 – 1612.; Dale O, Hjortkjaer R, Kharasch ED ( 2002 ). Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 46: 759 – 770.; Gomez‐Mantilla JD, Casabo VG, Schaefer UF, Permutation Lehr CM ( 2013 ). Permutation test (PT) and tolerated difference test (TDT): two new, robust and powerful nonparametric tests for statistical comparison of dissolution profiles. Int J Pharm 441: 458 – 467.; Gomez‐Mantilla JD, Schaefer UF, Casabo VG, Lehr T, Lehr CM ( 2014 ). Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations. Aaps J 16: 791 – 801.; Gronlund J, Saari TI, Hagelberg N, Neuvonen PJ, Olkkola KT, Miconazole Laine K ( 2011 ). Oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. Antimicrob Agents Chemother 55: 1063 – 1067.; Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, et al. ( 2001 ). Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84: 587 – 593.; Hao GT, Zhou HY, Gao HZ, Qu HY, Liang YG, Li YY, et al. ( 2014 ). Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain. Pharmacol Rep 66: 153 – 158.; Kalso E ( 2005 ). Oxycodone. J Pain Symptom Manage 29: S47 – S56.; Kim JY, Lee SH, Park CW, Rhee YS, Kim DW, Park J, et al. ( 2015 ). Design and in vivo evaluation of oxycodone once‐a‐day controlled‐release tablets. Drug Des Devel Ther 9: 695 – 706.; Kokki H, Rasanen I, Reinikainen M, Suhonen P, Vanamo K, Ojanpera I ( 2004 ). Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clin Pharmacokinet 43: 613 – 622.; Kokki M, Valitalo P, Kuusisto M, Ranta VP, Raatikainen K, Hautajarvi H, et al. ( 2014 ). Central nervous system penetration of oxycodone after intravenous and epidural administration. Br J Anaesth 112: 133 – 140.; Kokubun H, Yoshimoto T, Hojo M, Fukumura K, Matoba M ( 2014 ). Pharmacokinetics of oxycodone after intravenous and subcutaneous administration in Japanese patients with cancer pain. J Pain Palliat Care Pharmacother 28: 338 – 350.; Kosmidis K, Argyrakis P ( 2003 ) Fractal kinetics in drug release from finite fractal matrices. J Chem Phys 119: 6373 – 6377; Lalovic B, Kharasch E, Hoffer C, Risler L, Liu‐Chen LY, Shen DD ( 2006 ). Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79: 461 – 479.; Li CG, Huang XE, Li Y, Lu YY ( 2011 ). Clinical observations on safety and efficacy of OxyContin(R) administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev 12: 2477 – 2478.